Celiac Disease Pipeline Sees Surge in New Treatments

Over 25 companies developing 30+ therapies for the autoimmune disorder

Mar. 30, 2026 at 4:21pm

Got story updates? Submit your updates here. ›

According to a new report from DelveInsight, the global pipeline for celiac disease treatments has expanded significantly, with over 25 key companies working on developing more than 30 new therapies to address this autoimmune disorder.

Why it matters

Celiac disease affects millions worldwide, causing digestive issues and other health problems when gluten is consumed. The growing pipeline of potential new treatments reflects the high unmet need and increasing research focus on finding better ways to manage and treat this chronic condition.

The details

The report analyzes the current state of celiac disease clinical trials, therapies in development, their mechanisms of action, and routes of administration. It highlights the diverse approaches companies are taking to tackle this complex autoimmune disorder, from novel drug candidates to improvements on existing treatment options.

  • The report was published on March 30, 2026.

The players

DelveInsight

A leading healthcare consulting and market research firm that provides industry analysis and insights.

Got photos? Submit your photos here. ›

What’s next

The report provides a comprehensive overview of the celiac disease pipeline, which will be of interest to patients, healthcare providers, researchers, and pharmaceutical companies as they continue to explore new ways to manage this chronic condition.

The takeaway

The growing pipeline of celiac disease treatments signals progress in addressing an autoimmune disorder that has long lacked sufficient therapeutic options, offering hope for improved care and quality of life for those living with the condition.